Tirzepatide
Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist peptide that lowers blood sugar and drives weight loss, with up to 22.5% loss in trials.
Total Price
฿4900
For research & laboratory use only. Not for human consumption.
Half-Life
5 days
Administration Route
Subcutaneous injection
Dual Receptor Action
Targets GLP-1 & GIP simultaneously for superior fat loss
22.5% Body Weight Loss
Best-in-class efficacy proven in Phase 3 SURMOUNT trial
Cardiovascular Protection
Reduces HbA1c and improves lipid profile
Effect Timeline
Appetite noticeably reduced, portion sizes decrease naturally
3–5% body weight loss; blood sugar stabilising
Visible fat loss, especially around waist; energy stable
8–12% weight loss achieved; metabolic markers improved
Start — Week 1–2
Appetite noticeably reduced, portion sizes decrease naturally
Week 4
3–5% body weight loss; blood sugar stabilising
Week 8
Visible fat loss, especially around waist; energy stable
Week 16
8–12% weight loss achieved; metabolic markers improved
Mechanism of Action
Scientific Research
New England Journal of Medicine (2022)
New England Journal of Medicine (2021)
Why Researchers Choose Tirzepatide
Tirzepatide (the GLP-1 and GIP dual agonist marketed as Mounjaro) is studied wherever combined incretin pharmacology and strong weight reduction matter:
- Dual incretin receptor pharmacology and additive GIP plus GLP-1 engagement studies
- Body-weight reduction mechanisms and hypothalamic appetite signalling
- Glycaemic control and insulin-sensitivity studies in insulin-resistant research models
- Lipid metabolism and adipose-tissue remodelling investigations
- Comparative pharmacology against single-receptor GLP-1 agonists such as semaglutide
- Cardiovascular and metabolic risk-marker modulation in metabolic disease contexts
How Tirzepatide Works
Tirzepatide is a single 39-amino-acid peptide engineered to activate two incretin receptors at once: GLP-1 and GIP. A fatty-acid chain enables albumin binding for a roughly five-day half-life and once-weekly dosing. GLP-1 receptor activation drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite, while added GIP receptor engagement further enhances the insulin response and influences adipose-tissue metabolism. The combined action on both pathways is what produced larger weight and glucose effects than single-receptor GLP-1 agonists in clinical trials.
Tirzepatide vs. Semaglutide
Tirzepatide is a GLP-1 and GIP dual agonist, whereas semaglutide targets GLP-1 alone and retatrutide adds a third (glucagon) receptor. Comparing single-, dual- and triple-receptor pharmacology is a central theme in current incretin research. See the semaglutide vs. tirzepatide comparison for a side-by-side breakdown.
Tirzepatide Dosing Protocol
Titration: once-weekly subcutaneous, escalating every 4 weeks: 2.5mg → 5 → 7.5 → 10 → 12.5 → 15mg. Most protocols settle in the 5mg to 15mg weekly range; slow escalation manages gastrointestinal tolerability.
Reconstitution and Storage
Reconstitution: use bacteriostatic water (1 to 2ml per vial); swirl gently until fully dissolved, do not shake. After reconstitution: keep refrigerated, use within 28 days, and protect from direct light.
Dosing at a Glance
Route
Subcutaneous injection
Frequency
Once weekly
Typical research dose
2.5–15 mg
Opens the calculator with this peptide preselected. Research reference only.
Product FAQs
Customer Reviews
I recently started Milo-Lab's Tirzepatide after allowing myself to blow out over 15kg from my ideal body weight, and needed to get back into shape and overhaul my diet. I'm currently in Week 3, so it's early to post a review, but the results so far have been extraordinary, so I thought it might help others considering their own weight loss journey. My results so far: Starting weight: 99.80kg Week 1: 94.80kg (5kg loss) Week 2: 92.70kg (7.1kg loss) Week 3: 90.30kg (9.50kg loss) I started with a 48hr fast, and since then my diet has been 99% keto, with a little chocolate after dinner. My training is 5 x 10km runs while fasted in the morning. Zero side effects, and this product has allowed me to properly address my diet and eat clean without much effort. I've been a long-time customer of Milo-Lab, and after listening to Matt's recommendation, I'm absolutely delighted with this product and the results. Worth every cent and more.
Fantastic quality! Fast shipping and excellent service!
I tried 2.5mg and the dose feels pretty on point compared to other lab-tested Tirzepatide products I've run before. No hunger whatsoever for a couple of days!
Game changer, the best product on the market for weight loss!
Used in Research Stacks
GLP-1 Weight Loss Stack
Related Products
Semaglutide
Semaglutide (Ozempic) is a long-acting GLP-1 receptor agonist peptide that suppresses appetite and supports weight loss, with up to 14.9% reduction in STEP-1.
Retatrutide
Retatrutide (LY3437943) is Eli Lilly's investigational triple-receptor peptide targeting GLP-1, GIP and glucagon, with up to 24.2% weight loss in Phase 2.